// App-Quantinova.ai

P1060 : REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE

Researchers

Presenter

  • John Mascarenhas

Principal Investigators

  • Aaron T. Gerds

  • Jonathan K. Kish

  • Pranav Abraham

  • Alexandrina Balanean

  • Djibril Liassou

  • Bruce A. Feinberg

  • Ali McBride

  • Claire Harrison

Medical Centers

  • Bristol Myers Squibbs,Princeton,Vereinigte Staaten

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Cardinal Health,Dublin,États-unis

  • The Tisch Cancer Institute, Icahn Sc

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Guy's and St Thomas' NHS Foundation Trust,London,Royaume-uni

  • Guy's and St. Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Cardinal Health,Dublin,Stati Uniti

  • Cardinal Health,Dallas,United States

  • Cardinal Health,Dublin,Estados Unidos

  • Guy's and St

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Cleveland Clinic Taussig Cancer Institute,Cleveland,Verenigde Staten

  • Bristol Myers Squibb,Princeton,USA

  • Bristol Myers Squibb,Princeton, NJ,Estados Unidos

  • Cardinal Health,Dublin,Verenigde Staten

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Bristol Myers Squibbs,Princeton,Vereinigte Staaten

  • Cleveland Clinic Taussig Cancer Institute,Cleveland,Verenigde Staten

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • Cardinal Health,Dublin,Verenigde Staten

  • Cardinal Health, Dublin, OH

  • Bristol Meyers Squibb,Princeton,United States

  • Guy's and St. Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Bristol Myers Squibb,Princeton, NJ,Estados Unidos

  • Bristol Myers Squibb,Summit, NJ,Stati Uniti

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • White Blood Cell

Drug/Treatment

  • Ruxolitinib phosphate

  • Fedratinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved